Algeta announces first patient treated in phase II trial of Alpharadin to treat bone metastases in breast cancer
Clinical study underway in second tumor type
03-Feb-2010 -
Algeta ASA announced that it has treated the first patient in a phase II clinical study with Alpharadin for bone metastases resulting from endocrine-refractory breast cancer. This is the second tumor type under investigation with Alpharadin, the first being prostate cancer.
Algeta's lead ...
Belgium
biomarkers
bone metastases
+5